| Literature DB >> 31827765 |
Emilia Mikola1,2, Oscar Palomares3,4,5, Riitta Turunen6, Matti Waris7,8, Lotta E Ivaska1, Antti Silvoniemi1, Tuomo Puhakka1,2, Beate Rückert3,4, Tytti Vuorinen7,8, Mübeccel Akdis3,4, Cezmi A Akdis3,4, Tuomas Jartti9.
Abstract
BACKGROUND: Rhinovirus A and C infections are important contributors to asthma induction and exacerbations. No data exist on the interaction of local immune responses in rhinovirus infection. Therefore, we aimed to determine the tonsillar immune responses according to rhinovirus A, B and C infections.Entities:
Keywords: Allergy; Asthma; Children; Cytokine; Rhinovirus; Tonsil
Year: 2019 PMID: 31827765 PMCID: PMC6886181 DOI: 10.1186/s13601-019-0302-7
Source DB: PubMed Journal: Clin Transl Allergy ISSN: 2045-7022 Impact factor: 5.871
Fig. 1Study flow chart
Patient characteristics
| Characteristics | All, n = 42 | RV-A, n = 16 | RV-B, n = 12 | RV-C, n = 14 | |
|---|---|---|---|---|---|
| Age, years | 9.3 (2.6, 40) | 9.1 (2.6, 17) | 13.3 (4.8, 36) | 8.5 (3.2, 40) | 0.38 |
| Male | 23 (55%) | 11 (69%) | 2 (17%) | 10 (71%) | |
| Tonsillectomy and adenotomy | 22 (52%) | 9 (56%) | 6 (50%) | 7 (50%) | 0.93 |
| Self-smoking | 1/41 (2%) | 0 (0%) | 1 (8.3%) | 0/13 (0%) | 0.29 |
| Maternal smoking | 16/41 (39%) | 6 (38%) | 4/11 (36%) | 6 (43%) | 1.0 |
| Paternal smoking | 17/37 (46%) | 5/15 (33%) | 5/10 (50%) | 7/12 (58%) | 0.42 |
| Season of the surgery | |||||
| Winter (months 12–2) | 4 (9.5%) | 0 (0%) | 3 (25%) | 1 (7.1%) | 0.057 |
| Spring (months 3–5) | 11 (26%) | 8 (50%) | 0 (0%) | 3 (21%) | |
| Summer (months 6–8) | 6 (14%) | 4 (25%) | 0 (0%) | 2 (14%) | 0.21 |
| Fall (months 9–11) | 21 (50%) | 4 (25%) | 9 (75%) | 8 (57%) | |
| Indication of the surgery | |||||
| Obstruction only | 18 (43%) | 5 (31%) | 6 (50%) | 7 (50%) | 0.49 |
| Recurrent tonsillitis only | 8 (19%) | 2 (13%) | 2 (17%) | 4 (29%) | 0.55 |
| Obstruction + tonsillitis | 7 (17%) | 3 (19%) | 2 (17%) | 2 (14%) | 1.0 |
| Other | 9 (21%) | 6 (38%) | 2 (17%) | 1 (7.1%) | 0.14 |
| Respiratory symptoms on operation day | 13/39 (33%) | 10 (63%) | 1/10 (10%) | 2/13 (15%) | |
| Throat pain | 3/39 (7.7%) | 2 (13%) | 0/10 | 1/13 (7.7%) | 0.77 |
| Cough | 6/39 (15%) | 4 (25%) | 1/10 (10%) | 1/13 (7.7%) | 0.53 |
| Acute otitis media | 0/39 (0%) | 0 (0%) | 0/10 (0%) | 0/13 (0%) | – |
| Wheezing | 0/39 (0%) | 0 (0%) | 0/10 (0%) | 0/13 (0%) | – |
| Other | 1/39 (2.6%) | 1 (6.3%) | 0/10 (0%) | 0/13 (0%) | 1.0 |
| Respiratory symptoms within 2 weeks | 18/34 (53%) | 10/15 (67%) | 4/8 (50%) | 4/11 (36%) | 0.34 |
| Respiratory symptoms within 4 weeks | 22/34 (65%) | 11/15 (73%) | 5/8 (63%) | 6/11 (55%) | 0.66 |
| Total 25-OHD (nmol/l) | 54 (45, 66) | 54 (48, 68) | 51 (38, 64) | 58 (41, 69) | 0.72 |
| Free | 7.2 (5.3, 8.2) | 7.0 (5.7, 10) | 6.5 (4.3, 7.9) | 7.3 (5.3, 8.5) | 0.69 |
| Bioavailable | 2.4 (1.9, 3.0) | 2.5 (2.0, 4.0) | 2.1 (1.6, 2.7) | 2.4 (1.8, 3.3) | 0.45 |
| Self-reported allergy | 18 (43%) | 6 (38%) | 7 (58%) | 5 (36%) | 0.44 |
| Physician-diagnosed atopic dermatitis | 7/41 (17%) | 1 (6.3%) | 4 (33%) | 2/13 (15%) | 0.19 |
| Self-reported allergic rhinitis | 10/40 (25%) | 4 (25%) | 4/11 (36%) | 2/13 (15%) | 0.53 |
| Physician-diagnosed asthma | 8/40 (20%) | 1/15 (6.7%) | 5 (42%) | 2/13 (15%) | 0.099 |
| Sensitization | 14/33 (42%) | 3/11 (27%) | 5/9 (56%) | 6/13 (46%) | 0.45 |
| Food | 4/33 (12%) | 1/11 (9.1%) | 0/9 (0%) | 3/13 (23%) | 0.42 |
| Aeroallergen | 11/33 (33%) | 2/11 (18%) | 5/9 (56%) | 4/13 (31%) | 0.25 |
25-OHD, 25-hydroxyvitamin D
Data are expressed as median (range), or number of subjects (%)
Virus detection
| Virus | Nasopharynx | Tonsil | ||||||
|---|---|---|---|---|---|---|---|---|
| RV-A n = 16 | RV-B | RV-C n = 14 | RV-A | RV-B | RV-C | |||
| Adenovirus | 1 (6.3%) | 2 (17%) | 0 (0%) | 0.27 | 3 (19%) | 0 (0%) | 1 (7.1%) | 0.36 |
| Bocavirus-1 | 2 (13%) | 3 (25%) | 3 (21%) | 0.70 | 5 (31%) | 1 (8.3%) | 1 (7.1%) | 0.22 |
| Coronavirus | 3 (19%) | 0 (0%) | 0 (0%) | 0.10 | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
| Enterovirus | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 | 1 (6.3%) | 1 (8.3%) | 2 (14%) | 0.82 |
| Influenza A or B virus | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 | 0 (0%) | 0 (0%) | 0 (0%) | – |
| Metapneumovirus | 0 (0%) | 0 (0%) | 0 (0%) | – | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
| Parainfluenza virus types 1–3 | 2 (13%) | 0 (0%) | 0 (0%) | 0.32 | 2 (13%) | 0 (0%) | 1 (7.1%) | 0.77 |
| Respiratory syncytial virus | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
| Rhinovirus | 16 (100%) | 12 (100%) | 14 (100%) | – | 1 (6.3%) | 1 (8.3%) | 1 (7.1%) | 1.0 |
| Number of positive viruses | ||||||||
| 1 virus | 8 (50%) | 8 (67%) | 11 (79%) | 0.26 | 4 (25%) | 1 (8.3%) | 6 (43%) | 0.15 |
| 2 viruses | 5 (31%) | 3 (25%) | 3 (21%) | 0.91 | 2 (13%) | 1 (8.3%) | 0 (0%) | 0.49 |
| 3 viruses | 3 (19%) | 1 (8.3%) | 0 (0%) | 0.29 | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
| 4 viruses | 0 (0%) | 0 (0%) | 0 (0%) | – | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
| ≥ 1 viruses | 16 (100%) | 12 (100%) | 14 (100%) | – | 8 (50%) | 2 (17%) | 6 (43%) | 0.18 |
| ≥ 2 viruses | 8 (50%) | 4 (33%) | 3 (21%) | 0.26 | 4 (25%) | 1 (8.3%) | 0 (0%) | 0.11 |
| ≥ 3 viruses | 3 (19%) | 1 (8.3%) | 0 (0%) | 0.29 | 2 (13%) | 0 (0%) | 0 (0%) | 0.32 |
| ≥ 4 viruses | 0 (0%) | 0 (0%) | 0 (0%) | – | 1 (6.3%) | 0 (0%) | 0 (0%) | 1.0 |
Data are expressed as number of subjects (%)
Cytokine or transcription factor expression
| Cytokine or | RV-A | RV-B | RV-C | Adjustments | ||
|---|---|---|---|---|---|---|
| Th1 -type | ||||||
| IFN-γ | 71* (27, 104) | 58 (34, 72) | 72 (33, 98) | 0.99 | 0.61 | Spring |
| Tbet | 72 (27, 309) | 33 (15, 60) | 40 (15, 70) | 0.082 | 0.056 | Respiratory symptoms, spring |
| Th2 -type | ||||||
| IL-13 | 0.40 (0.018, 5.0) | 0.37 (0.020, 3.4) | 1.8 (0.36, 7.6) | 0.14 | 0.14 | – |
| GATA3 | 31 (13, 50) | 20 (6.2, 33) | 21 (12, 37) | 0.36 | 0.98 | Spring |
| Th17 -type | ||||||
| IL-17 | 15 (9.1, 26) | 14 (3.8, 26) | 8.0 (4.0, 14) | 0.37 | 0.36 | Age |
| RORC2 | 22 (9.7, 71) | 18 (7.2, 29) | 14 (6.2, 25) | 0.31 | Respiratory symptoms | |
| Treg -type | ||||||
| IL-10 | 55 (32, 84) | 40 (14, 62) | 33 (22, 74) | 0.34 | 0.96 | Age, spring |
| IL-37 | 0.38 (0.14, 0.50) | 0.22** (0.14, 0.34) | 0.27 (0.14, 0.34) | 0.64 | 0.11 | Respiratory symptoms |
| FOXP3 | 56 (19, 107) | 33 (13, 89) | 29 (16, 88) | 0.47 | 0.12 | Rhinitis |
| TGF-β | 146 (94, 185) | 192 (108, 252) | 139 (102, 187) | 0.49 | 0.49 | – |
| Type I/III interferons | ||||||
| IFN-α | 5.8 (0, 44) | 0.37** (0.33, 38) | 22 (2.9, 78) | 0.23 | Respiratory symptoms | |
| IFN-β | 15 (3.3, 81) | 4.9 (2.2, 68) | 61 (7.7, 116) | 0.30 | 0.30 | – |
| IL-28 | 25* (1.4, 88) | 9.7 (1.4, 62) | 32 (13, 109) | 0.41 | 0.41 | – |
| IL-29 | 5.9 (1.3, 35) | 3.1 (1.3, 22) | 11 (4.4, 40) | 0.53 | 0.53 | – |
IFN interferon, Tbet T-box transcription factor, IL interleukin, GATA3 GATA-binding factor 3, RORC RAR-related orphan receptor C, FOXP forkhead box protein, TGF tumour growth factor, Th T helper cell, Treg T regulatory cell
Values are arbitrary units × 104 relative to EF1α
Data are expressed as median (interquartile range)
Adjustments are selected backward stepwise from significant differences between groups (sex, rhinitis on the operation day, any respiratory symptoms on the operation day, operation made spring, operation made fall) and age
*n = 15
**n = 11
Fig. 2Relative tonsillar expression of IFN-α. Comparison of tonsil samples between 16 RV-A, 12 RV-B and 14 RV-C positive patients (Table 3). Values are arbitrary units × 104 relative to EF1α. Data represents median with interquartile range. The median of RV-B is 0.37. IFN, interferon
Fig. 3Relative tonsillar expression of RORC2. Comparison of tonsil samples between 16 RV-A, 12 RV-B and 14 RV-C positive patients (Table 3). Values are arbitrary units × 104 relative to EF1α. Data represents median with interquartile range. RORC2, RAR-related orphan receptor C 2
Fig. 4Relative tonsillar expression of Tbet. Comparison of tonsil samples between 16 RV-A, 12 RV-B and 14 RV-C positive patients (Table 3). Values are arbitrary units × 104 relative to EF1α. Data represents median with interquartile range. Tbet, T-box transcription factor